芪苈强心胶囊联合瑞舒伐他汀对冠心病合并急性心律失常老年患者的疗效及血清炎症因子水平的影响  

Clinical effect of Qiliqiangxin capsule combined with Rosuvastatin on elderly patients with coronary heart disease complicated with acute arrhythmia and influence on serum inflammatory factors

作　　者：宋红星[1] 张杰[1] 马龙飞[1] 范燕宾 何冉[1] 鲁召辉 韩欣宇[1] 郭赫立 SONG Hong-xing;ZHANG Jie;MA long-Fei;FAN Yan-bin;HE Ran;LU Zhao-hui;HAN Xin-yu;GUO He-li(Department of Cardiovascular Medicine,the Seventh Peoples Hospital of Zhengzhou City,Zhengzhou 450000,China)

机构地区：[1]郑州市第七人民医院心血管内科,郑州450000

出　　处：《医药论坛杂志》2023年第22期38-42,共5页Journal of Medical Forum

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20220831)。

摘　　要：目的本文探究冠心病合并急性心律失常采用芪苈强心胶囊联合瑞舒伐他汀治疗的疗效及对血清炎症因子各指标的影响。方法选取2022年2月—2023年2月郑州市第七人民医院心内科收治的116例冠心病合并急性心律失常老年患者,按治疗方法不同分组,采用瑞舒伐他汀进行治疗的58例作为参照组,采用瑞舒伐他汀联合芪苈强心胶囊治疗的58例作为研究组,比较两组疗效并观察治疗前后血清炎症因子白介素-6(IL-6)、白介素-8(IL-8)及肿瘤坏死因子-a(TNF-a)的改善情况。结果(1)研究组治疗有效率96.55%,高于参照组的82.76%(P<0.05)。(2)治疗前两组IL-6、IL-8、TNF-α水平比较无统计学意义(P>0.05),治疗后两组的因子水平均降低,并且研究组分别是(75.40±7.30)ng/L、(7.30±1.39)ng/mL和(22.01±3.44)ng/L,明显低于参照组(P<0.05)。(3)治疗前两组血黏度指标比较无统计学意义(P>0.05),治疗后两组患者的血黏度指标均下降,且研究组FIB、血浆黏度、全血黏度(低切)及全血黏度(高切)分别是(2.29±0.69)g/L、(1.29±0.40)mPa·s、(10.29±2.09)mPa/s和(3.96±0.87)mPa/s,均低于参照组各指标(P<0.05)。(4)治疗前组间患者的心功能指标对比无统计学意义(P>0.05),治疗后研究组LVEF(47.64±3.20),高于参照组、LVESE及LVEDV分别是(80.55±17.49)mL和(160.09±19.22)mL,低于参照组(P<0.05)。结论老年冠心病合并急性心律失常采用芪苈强心胶囊联合瑞舒伐他汀能改善肿瘤坏死因子-a(TNF-a)、白介素-6(IL-6)、白介素-8(IL-8)指标水平,改善患者的心功能以及血黏度指标,提升治疗效果,可临床推广。Objective To investigate the effect of Qiliqiangxin capsule combined with rosuvastatin on coronary heart disease complicated with acute arrhythmia and its effect on serum inflammatory factors.Methods A total of 116 elderly patients with coronary heart disease complicated with acute arrhythmia admitted to the Department of Cardiology of the Seventh People's Hospital of Zhengzhou from February 2022 to February 2023 were selected.Divided into groups according to different treatment methods,58 cases were treated with rosuvastatin as the reference group,and 58 cases were treated with rosuvastatin combined with Qiliqiangxin capsule as the study group.The efficacy of the two groups was compared and the improvement of serum inflammatory factors interleukin-6(IL-6),interleukin-8(IL-8)and tumor necrosis factor-A(TNF-a)before and after treatment was observed.Results(1)The effective rate of the study group(96.55%)was higher than that of the reference group(82.76%)(P<0.05).(2)There was no significant difference in IL-6,IL-8 and TNF-αlevels between the two groups before treatment(P>0.05),and the levels of factors in the two groups were decreased after treatment,and the study groups were(75.40±7.30)ng/L,(7.30±1.39)ng/mL and(22.01±3.44)ng/L,respectively.It was significantly lower than that in the reference group(P<0.05).(3)There was no significant difference in blood viscosity between the two groups before treatment(P>0.05),the blood viscosity indexes of the two groups decreased after treatment.In addition,the FIB,plasma viscosity,whole blood viscosity(low cut)and whole blood viscosity(high cut)of the study group were(2.29±0.69)g/L,(1.29±0.40)mPa·s,(10.29±2.09)mPa·s and(3.96±0.87)mPa·s,respectively,which were lower than those of the reference group(P<0.05).(4)There was no statistical significance in the comparison of cardiac function indexes between groups before treatment(P>0.05).After treatment,LVEF(47.64±3.20)in the study group was higher than that in the reference group,LVESE and LVEDV were(80.55±17.49)mL and(16

关 键 词：芪苈强心胶囊 瑞舒伐他汀 冠心病 治疗有效率 心律失常 心功能 

分 类 号：R541.4[医药卫生—心血管疾病]